CAR-T therapy, Chimeric Antigen Receptor T-cell therapy, a form of engineered immune treatment, works by taking a patient's own immune cells and re-engineering them to recognise and attack cancer cells.
Doctors then return the modified cells to the patient's body.
In some blood cancers, this has produced lasting remission in patients who had run out of other options.
Courses in the United States and Europe have cost hundreds of thousands of dollars. was set up in New Delhi in 2021 to develop and manufacture these therapies inside India.
It was founded by Dr Gaurav Kharya, a paediatric haematologist and stem cell transplant specialist, along with co-founder Dr Tanveer Ahmad.
